KCT0008808RecruitingUnknown
Exploring HER2 Overexpression and its Significance as a Biomarker in pathologic T-stage of de novo Muscle-Invasive Bladder Cancer: A prospective study in Retrospective multicenter Cohort
Trial Snapshot
- Phase
- Unknown
- Status
- Recruiting
- Sponsor
- GangNeung Asan Hospital
- Enrollment
- 174
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 18(Year) to o Limit (—)
- Sex
- All
Inclusion Criteria
- •The patients were recently diagnosed with urothelial cancer and had no history of urothelial cancer. Patients who underwent transurethral resection of bladder tumor at Gangneung Asan Hospital between January 2005 and December 2013.
Exclusion Criteria
- •If have a upper urinary tract cancer is diagnosed
- •diagnosed metastasized carcinoma
- •If the carcinoma is not a cancer originating in the urinary tract epithelium
Investigators
Similar Trials
Completed
Not Applicable
Prognostic significance of HER2 expression in patients with resectable gastric cancerGastric adenocarcinomaCancerISRCTN54802594Inje University Busan Paik Hospital782
Recruiting
Not Applicable
Interrelationship of Serum HER2-ECD with Pathological HER2 level (Human Epidermal Growth Factor Receptor Type2 - Extra Cellular Domain) in Operable Gastric Cancer Patients in JapaGastric CancerJPRN-UMIN000006048Shizuoka General Hospital60
Completed
Not Applicable
Observational study of serum HER2 in HER2 positive advanced gastric cancer treated with trastuzumab in combination with capecitabine plus cisplatin(XP+H)Gastric cancerJPRN-UMIN000006445Sapporo Medical University 1st department of Internal Medicine10
Unknown
Phase 2
Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid TumorHER-2 Protein OverexpressionHER-2 Gene AmplificationNCT04215159Jin-Hee Ahn42
Unknown
Not Applicable
HER2 Positive CTC in Advanced Gastric CancerHER2 Positive Advanced Gastric CancerNCT01847794Peking University50